Digest Network Come funziona
Network
/
Società
Tu
Non verificato

Tubulis

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

10 comunicati stampa

Guarda tutti i comunicati
30/10/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Vetrine/Shopping
Medicina - Varie
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)
Fonte
Tubulis
Emittente
Business Wire
1.00
0
19/10/2025
Scienza
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
Eventi
Industria
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
Fonte
Tubulis
Emittente
Business Wire
1.00
0
15/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline
Fonte
Tubulis
Emittente
Business Wire
1.00
0
22/09/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Tubulis to Present First Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-Resistant Ovarian Cancer in Late-Breaking Oral Presentation at ESMO 2025
Fonte
Tubulis
Emittente
Business Wire
1.00
0
09/09/2025
Scienza
Legge/Diritto
Biotecnologia
Farmaceutica
Oncologia
Salute
Associazioni/Professionisti
Mercato del lavoro
Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer
Fonte
Tubulis
Emittente
Business Wire
1.00
0
06/02/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
Fonte
Tubulis
Emittente
Business Wire
1.00
0
30/01/2025
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Industria
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
Fonte
Tubulis
Emittente
Business Wire
1.00
0
17/12/2024
Eventi
Biotecnologia
Farmaceutica
Salute
Oncologia
Tubulis to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Fonte
Tubulis
Emittente
Business Wire
1.00
0
05/08/2024
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Eventi
Industria
Fierce Biotech Names Tubulis a "Fierce 15" Biotech Company of 2024
Fonte
Tubulis
Emittente
Business Wire
1.00
0
27/06/2024
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
Fonte
Tubulis
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0